Perceptions of flatulence from bean consumption among adults in 3 feeding studies

Nutrition Program, School of Nutrition and Health Promotion, Arizona State University, 500 North 3rd Street, Phoenix, AZ 85004 USA.
Nutrition Journal (Impact Factor: 2.6). 11/2011; 10(1):128. DOI: 10.1186/1475-2891-10-128
Source: PubMed


Many consumers avoid eating beans because they believe legume consumption will cause excessive intestinal gas or flatulence. An increasing body of research and the 2010 Dietary Guidelines for Americans supports the benefits of a plant-based diet, and legumes specifically, in the reduction of chronic disease risks. The purpose of the current research was to investigate the perception of increased flatulence and gastrointestinal discomfort among participants who consumed a ½ cup of beans daily for 8 or 12 weeks.
Participants in three studies to test the effects of beans on heart disease biomarkers completed the same weekly questionnaire to assess gastrointestinal discomfort issues such as increased flatulence, stool changes, and bloating. Studies 1 and 2 were randomized crossover trials. Participants consumed ½ cup of pinto beans, black-eyed peas, and canned carrots as control (n = 17) in Study 1 for three randomized 8-week phases. For Study 2, participants ate ½ cup baked beans or canned carrots as control (n = 29) for two randomized 8-week phases. Study 3 was a parallel arm trial with 40 subjects receiving ½ cup pinto beans and 40 consuming a control soup for 12 weeks. Changes in the frequency of perceived flatulence, stool characteristics, and bloating were the primary outcome measures. Chi-square distributions were examined for the presence or absence of symptoms and demographic characteristics to determine differences by gender, age, body mass index (BMI), and bean type.
Less than 50% reported increased flatulence from eating pinto or baked beans during the first week of each trial, but only 19% had a flatulence increase with black-eyed peas. A small percentage (3-11%) reported increased flatulence across the three studies even on control diets without flatulence-producing components.
People's concerns about excessive flatulence from eating beans may be exaggerated. Public health nutritionists should address the potential for gastrointestinal discomfort when increasing fiber intake from beans with clients. It is important to recognize there is individual variation in response to different bean types.

Download full-text


Available from: Andrea M Hutchins
  • Source
    • "The dosing of pre- and probiotics used in SYNERGY is based on previous successful trials [30,36,37]. However, in order to minimise the side effects reported in previous studies, such as flatulence and bloating [38], the synbiotics will commence at half dose for the first 3 weeks. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Emerging evidence suggests modulating the microbiota in the large bowel of patients with chronic kidney disease (CKD) through pre- and/probiotic supplementation may inhibit the development of key nephrovascular toxins. To date, quality intervention trials investigating this novel treatment in CKD are lacking. The aim of SYNERGY is to assess the effectiveness of synbiotics (co-administration of pre- and probiotics) as a potential treatment targeting the synthesis of uremic toxins, specifically, indoxyl sulphate (IS) and p-cresyl sulphate (PCS). Methods/design: Thirty-seven patients with moderate to severe CKD (Stage IV and V, pre-dialysis) will be recruited to a double-blind, placebo-controlled, randomised cross-over trial. Patients will be provided with synbiotic therapy or placebo for 6 weeks, with a 4 week washout before cross-over. The primary outcome is serum IS, total and free (unbound) concentrations, measured using ultra-performance liquid chromatography. Secondary outcomes include serum PCS, total and free (unbound) concentrations; cardiovascular risk, measured by serum lipopolysaccharides, serum trimethylamine-N-oxide (TMAO) and inflammation and oxidative stress markers; kidney damage, measured by 24 hour proteinuria and albuminuria, estimated glomerular filtration rate and renal tubule damage (urinary kidney injury molecule-1); patients' self assessed quality of life; and gastrointestinal symptoms. In addition, the effects on the community structure of the stool microbiota will be explored in a subset of patients to validate the mechanistic rationale underpinning the synbiotic therapy. Discussion: IS and PCS are two novel uremic toxins implicated in both cardiovascular disease (CVD) and progression of CKD. Preliminary studies indicate that synbiotic therapy maybe a promising strategy when considering a targeted, tolerable and cost-efficient therapy for lowering serum IS and PCS concentrations. This trial will provide high quality 'proof-of-concept' data to elucidate both the efficacy of synbiotic therapy for lowering the toxins and whether reductions in serum IS and PCS translate into clinical benefits. Considering the potential of pre- and probiotics to not only shift toxin levels, but to also impede CVD and CKD progression, SYNERGY will provide vital insight into the effectiveness of this innocuous nutritional therapy. Trial registration: Universal Trial Number: U1111-1142-4363. Australian New Zealand Clinical Trials Registry Number: ACTRN12613000493741, date registered: 2nd May 2013.
    Full-text · Article · Jul 2014 · BMC Nephrology
  • Source
    • "Our findings confirm that of another study where concerns over gastrointestinal discomforts may be overstated, especially when individuals gradually increase dry bean consumption [32]. Winham and Hutchins found that more than half of their study participants did not report gastrointestinal distress after 1 week of consuming ½ cup of beans per day and over 70% had no symptoms after the second week on study [32]. These findings indicate that gastrointestinal symptoms should not be considered a major concern for most people when increasing bean consumption. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Emerging evidence supports that increased consumption of dry beans (Phaseolus vulgaris L.) reduces both the incidence and recurrence of adenomatous polyps or precancerous growths. Navy beans have been studied for dietary colorectal cancer (CRC) chemoprevention in animal models. Our main objectives were to assess the feasibility of increased navy bean consumption in adults with and without history of CRC and to achieve intake amounts associated with chemoprevention. Methods: Seven meals and six snacks were developed for both the absence and inclusion of cooked navy bean powder (35grams/day). Sixteen healthy adults (7 non-cancer and 9 CRC survivors) completed the placebo-controlled, randomized, single-blinded dietary intervention trial. Participants consumed one study-provided meal and snack daily for 28 days, which accounted for approximately one-third of their total recommended caloric intake (meals = 202-483 kcal and snacks = 194-401 kcal). Participants also recorded three-day dietary food logs each week. Results: The addition of 35g of cooked navy bean powder (NBP) into foods provided 5-8% daily caloric intake. The compliance to the meal and snack intervention ranged from 89-100%. Non-cancer participants in the NBP group had a significant decrease in total caloric intake after week 4 (p≤0.0001). CRC survivors in the NBP group significantly increased total fiber intake by week 4 (p≤0.0001). Conclusions: NBP are feasible to include in meals for increased total fiber intake and for consuming the amount that is associated with CRC chemoprevention outcomes. These findings warrant further evaluation of NBP consumption in clinical nutrition trials for CRC control and prevention.
    Full-text · Article · May 2014 · Current Nutrition & Food Science
  • [Show abstract] [Hide abstract]
    ABSTRACT: To summarize the relevant publications during the last 12 months supporting that diet can influence gas-related symptoms in the absence of a malabsorption state. Gas symptoms during carbohydrate fermentation: a diet incorporating beans is well tolerated by a majority of individuals involved in a program of heart disease biomarkers. By contrast, in patients with irritable bowel syndrome, a diet avoiding fermentable carbohydrates improved gas-related abdominal symptoms. The rate of fermentation determines the production of abdominal symptoms, and many slowly fermentable fibers have a rapid fermentation profile that can generate abdominal symptoms. Modulation of visceral sensitivity: diet can influence gas symptoms by increasing the tolerability of the intestine to gas. Capsaicin decreases visceral hyperalgesia and improved bloating in patients with irritable bowel syndrome. Changes in gas-producing bacteria: different strains of Lactobacillus have antimicrobial properties against gas-forming coliforms. New clinical studies show beneficial effects of prebiotics and probiotics on abdominal bloating. Actual data suggest that diet could improve gas-related abdominal symptoms acting on several mechanisms: gas production, visceral hypersensitivity and modulation of gas-producing enteric bacteria.
    No preview · Article · Jul 2012
Show more